Methyl aminolevulinate
![]() | |
Names | |
---|---|
| |
External links | |
AHFS/Drugs.com | Multum Consumer Information |
Chemical and physical data | |
Formula | C6H11NO3 |
Molar mass | 145.158 g·mol−1 |
3D model (JSmol) | |
| |
|
Methyl aminolevulinate (MAL) is a drug used as a sensitizer in photodynamic therapy. It is a prodrug that is metabolized to protoporphyrin IX. It is marketed as Metvix.
Metvix cream is applied topically and some time later the skin is illuminated with a proprietary red light (630 nm) source (medical lamp 'Aktilite') to activate the photosensitiser.
Metvix is developed by Photocure and Galderma has bought all rights to Metvix.[1]
Approvals and indications
Methyl aminolevulinate is approved in New Zealand for treatment of basal cell carcinoma.[2]
It is now approved in many countries and has been used to treat non-melanoma skin cancer (including basal cell carcinoma).[3]
It has some advantages over Levulan.[4]
It has been reported as controversial in some quarters, with severe pain allegedly being experienced by some patients. [5]
Interim result of phototherapy for actinic keratosis with Metvix one week after exposure. Patient has light skin and blue eyes.
References
- ↑ "Photocure Divests Metvix to Galderma for EUR 51 Million". Archived from the original on 2011-02-07. Retrieved 2010-09-10.
- ↑ Ngan V (2003). "Methyl aminolevulinate photodynamic therapy (MAL PDT)". DermNet NZ. Archived from the original on 2016-06-28. Retrieved 2021-06-28.
- ↑ "New 5 Year Metvix-PDT Data Demonstrate Long-Term Efficacy & Reliability For NM Skin Cancer Treatment". EurekAlert!. 2006. Archived from the original on 2021-08-28. Retrieved 2021-06-28.
- ↑ O'Connor AE, Gallagher WM, Byrne AT (2009). "Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy". Photochemistry and Photobiology. 85 (5): 1053–74. doi:10.1111/j.1751-1097.2009.00585.x. PMID 19682322. S2CID 205950773.
- ↑ "Concerns raised over ALA skin cancer cream as patients recount 'horrendous' pain". Australian Broadcasting Corporation. 16 November 2013. Archived from the original on 2018-09-22. Retrieved 2021-06-28.
External links
Identifiers: |
|
---|
- Pages using duplicate arguments in template calls
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Articles with changed EBI identifier
- Prodrugs
- Antineoplastic drugs
- Methyl esters
- Ketoesters
- All stub articles
- Antineoplastic and immunomodulating drug stubs